Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

History

Since its formation in 2003, Sio Gene Therapies has been translating pioneering research into treatments that can help millions of people around the world suffering from genetic disorders. Working closely with academic, industry, government and medical partners, our team of scientists have been able to take first-in-class gene-editing treatments from bench to bedside. Our goal is to become one of the world’s leading gene therapy companies by developing new treatments for a wide range of serious genetic diseases.

Mission

Our mission is to build a platform for gene-editing treatments that can transform the lives of people living with genetic diseases.

Vision

Our vision is to become the world’s leader in gene-editing treatments, providing novel therapies for serious genetic diseases.

Key Team

Mr. David W. Nassif J.D. (CEO, CFO, Chief Accounting Officer, Gen. Counsel & Director)

Ms. Raquel Crystal (Head of HR & Operations)

Dr. Guangping Gao Ph.D. (Chief AAV Scientific Advisor)

Recognition and Awards

Sio Gene Therapies has received numerous awards and recognition, including two Nobel Prizes in Physiology or Medicine and two Scripps Translational Science Institute Awards.